STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in ALK-rearranged lung cancer

The signal transducer and activator of transcription 3 (STAT3) has been suggested to play a prominent role in mediating non–small-cell lung cancer (NSCLC) resistance to some tyrosine kinase inhibitor (TKI)-mediated therapies. Using a model of anaplastic lymphoma kinase gene (ALK)-translocated NSCLC...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cell Cycle
Main Authors: Cuyàs, Elisabet, Pérez-Sánchez, Almudena, Micol, Vicente, Menendez, Javier A., Bosch-Barrera, Joaquim
Format: Artigo
Jezik:Inglês
Izdano: Taylor & Francis 2016
Teme:
Report
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5224449/
https://ncbi.nlm.nih.gov/pubmed/27753543
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384101.2016.1245249
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki